Hydrea

Hydrea is an oral tablet formulation of hydroxycarbamide (hydroxyurea) with an unspecified strength, marketed in the European Union as a prescription antineoplastic agent. It belongs to the antimetabolite drug class and is used under medical supervision for several hematologic and oncologic conditions. The tablet is taken by mouth and requires a health‑care provider’s prescription. The medication is regulated as a prescription‑only product and is not available over the counter.

Hydrea is indicated for several chronic blood disorders and selected solid tumors, where it helps control abnormal cell proliferation.

- Chronic myeloid leukemia (CML) in patients who have not responded adequately to other therapies. - Polycythemia vera to reduce elevated red blood cell mass and lower risk of thrombosis. - Essential thrombocythemia for managing high platelet counts and preventing thrombotic events. - Sickle cell disease to increase fetal hemoglobin levels and reduce vaso‑occlusive crises. - Melanoma as part of combination chemotherapy regimens in certain clinical settings.

Hydrea may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common: - Nausea, vomiting, or loss of appetite. - Mild to moderate bone marrow suppression leading to anemia, neutropenia, or thrombocytopenia. - Skin changes such as hyperpigmentation or rash. - Elevated liver enzymes indicating hepatic irritation.

Serious: - Severe bone marrow failure with pancytopenia. - Acute renal impairment or nephrotoxicity. - Life‑threatening infections due to profound neutropenia. - Pulmonary toxicity, including interstitial pneumonitis.

Before starting Hydrea, clinicians should evaluate several safety considerations to minimize risk.

- Perform baseline complete blood count and liver function tests. - Monitor blood counts regularly during therapy to detect marrow suppression early. - Use caution in patients with pre‑existing renal or hepatic impairment. - Avoid use during pregnancy; the drug is classified as pregnancy category D. - Counsel women of child‑bearing potential about effective contraception throughout treatment and for a defined period after discontinuation. - Assess for history of hypersensitivity to hydroxyurea or related compounds.

Hydrea can interact with other medicines, affecting its efficacy or increasing toxicity.

Avoid: - Concurrent use of other myelosuppressive agents (e.g., chemotherapy, azathioprine) that may exacerbate bone marrow depression. - Strong CYP2C9 inhibitors that could increase hydroxycarbamide plasma levels. - Live vaccines, because immunosuppression may reduce vaccine effectiveness and increase infection risk.

Use with caution: - Allopurinol, which may enhance hematologic toxicity. - NSAIDs or aspirin, which can increase the risk of gastrointestinal bleeding. - Antiretroviral drugs such as zidovudine, which may have additive bone marrow effects.